MedTrace Logo

EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19

NCT05059106 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 29637

Last updated 2021-09-28

No results posted yet for this study

Summary

This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years from Viana city - Espírito Santo (ES)/Brazil, on the incidence of new cases over 12 months following treatment, compared to an external group from same state and adjusted for socio-demographic and epidemiological variables.

Conditions

Interventions

BIOLOGICAL

Half dose of ChAdOx1 nCoV-19 (AZD1222)

Vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all adults aged 18 to 49 years, from non-priority groups, from Viana city - Espírito Santo (ES)/Brazil.

BIOLOGICAL

Standard dose of ChAdOx1 nCoV-19 (AZD1222)

Vaccination with standad dose of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, in external cohort of health workers aged 18 to 49 years.

Sponsors & Collaborators

  • Centro de Pesquisas René Rachou

    collaborator OTHER_GOV

  • Escola Nacional de Saúde Pública Sérgio Arouca/Fiocruz

    collaborator UNKNOWN

  • Oswaldo Cruz Foundation

    collaborator OTHER

  • Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória

    collaborator UNKNOWN

  • Federal University of Espirito Santo

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-06-01
Completion
2022-10-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059106 on ClinicalTrials.gov